COMPOUND PROFILE / PEPTIDES & ANALOGUES
Davunetide / NAP.
Research draftDavunetide, also called NAP, is an ADNP-derived experimental neuroprotective peptide.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Davunetide, also called NAP, is an ADNP-derived experimental neuroprotective peptide.
Mechanism
It interacts with microtubule-related cellular processes.
Human research
A randomised progressive supranuclear palsy trial did not establish clinical benefit. This negative result remains part of the profile.
Preclinical & other research
Cell work investigated microtubule protection and tau-related mechanisms.
Safety & unknowns
Experimental protection does not guarantee clinical efficacy or long-term safety.
Regulatory status
Investigational; no approved neurodegenerative indication is established here.
Reported use & evidence
The supplied Davunetide / NAP profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.